|
Index of reports
> All cases (252)
> Cases with Pyrexia (22)
Below is the selection of adverse event reports related to Depakene (Valproic Acid) that includes all cases where reactions include pyrexia.
Adverse event in 20 year old male receiving Depakene (Valproic Acid)
Reported by a physician from France on 2007-10-30
Patient: 20 year old male, weighing 70.0 kg (154.0 pounds)
Adverse reactions / side effects: Respiratory Disorder, Blood Creatine Phosphokinase Increased, High Density Lipoprotein Increased, Lymphadenopathy, Urinary Incontinence, Visual Acuity Reduced, Ulcerative Keratitis, Pyrexia, Transaminases Increased, Obstructive Uropathy, C-Reactive Protein Increased, Acute Respiratory Distress Syndrome, Dermatitis Bullous, Mucous Membrane Disorder, Cough, Mechanical Ventilation, Back Pain, Dysphagia, Toxic Epidermal Necrolysis, Corneal Opacity, Prothrombin Time Ratio Decreased, Blood Creatine Phosphokinase MB Increased, Heart Rate Decreased, Rash Erythematous, Ureteral Catheterisation, Renal Colic, Skin Exfoliation, Eye Discharge, Corneal Neovascularisation, Symblepharon, Scab, Intubation, Nephrolithiasis, Corneal Transplant, Microlithiasis, Bone Marrow Failure, Thrombocytopenia, Renal Failure Acute, Catheter Related Complication, Depilation, Cataract, Iris Adhesions, Lacrimation Decreased, Alopecia, Lithotripsy, Asthenia, Leukopenia
Adverse event resulted in: life threatening event, hospitalization, disablity
Suspect drug(s):
Depakene
Dosage: 1.6 g daily
Indication: Partial Seizures
End date: 2004-11-22
Trileptal
Dosage: 600 mg, bid
Administration route: Oral
Indication: Partial Seizures
Start date: 2005-02-14
End date: 2005-02-21
Depakene
Dosage: 1 g daily
Administration route: Oral
Indication: Partial Seizures
Start date: 2004-11-23
End date: 2004-11-23
Depakene
Dosage: 1.5 g daily
Start date: 2004-11-24
End date: 2005-02-21
Aspegic 325
Indication: Influenza Like Illness
Start date: 2005-02-01
Other drugs received by patient: Rivotril
Adverse event in female receiving Depakene (Valproic Acid)
Reported by a physician from France on 2007-10-25
Patient: female
Adverse reactions / side effects: Hypersensitivity, Angioedema, Lymphadenopathy, Urticaria, Disseminated Intravascular Coagulation, Nuclear Magnetic Resonance Imaging Brain Abnormal, Pyrexia, Convulsion, Mucosal Inflammation, Oedema, Platelet Count Decreased, Prothrombin Level Decreased
Adverse event resulted in: hospitalization
Suspect drug(s):
Lamictal
Administration route: Oral
Indication: Epilepsy
Start date: 2007-09-12
End date: 2007-10-15
Depakene
Administration route: Oral
Indication: Epilepsy
Keppra
Administration route: Oral
Indication: Epilepsy
Start date: 2007-10-15
Adverse event in female receiving Depakene (Valproic Acid)
Reported by a health professional (non-physician/pharmacist) from France on 2007-10-18
Patient: female, weighing 2.7 kg (5.9 pounds)
Adverse reactions / side effects: Oral Intake Reduced, Dyspnoea, Corynebacterium Infection, Pyrexia, Nasal Congestion, Myoclonus, Malaise, Microcephaly, Feeding Disorder Neonatal, Eye Movement Disorder
Adverse event resulted in: hospitalization
Suspect drug(s):
Depakene (Valproic Acid)
Adverse event in female receiving Depakene (Valproic Acid)
Reported by a pharmacist from France on 2007-10-15
Patient: female
Adverse reactions / side effects: Confusional State, Hypersensitivity, Depersonalisation, Multiple Myeloma, Pyrexia, Hepatitis, Loss of Consciousness, Hypokinesia, Spinal Compression Fracture, Skin Lesion, Inappropriate Antidiuretic Hormone Secretion, Humerus Fracture, Back Pain, Phlebitis, Pain in Extremity, Musculoskeletal Pain, Hyponatraemia, Amnesia, Epilepsy, Spondylitis, Renal Failure, Respiratory Failure, Staphylococcal Infection, Sepsis, Blood Pressure Decreased
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Depakene
Administration route: Oral
Indication: Facial Neuralgia
Start date: 2004-10-18
End date: 2004-11-01
Hydrochlorothiazide
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Start date: 1999-01-01
End date: 2004-11-01
Other drugs received by patient: Amlodipine; Irbesartan; Omeprazole; Domperidone; Nitrofurantoin; Nifedipine
Adverse event in female receiving Depakene (Valproic Acid)
Reported by a pharmacist from France on 2007-10-12
Patient: female
Adverse reactions / side effects: Confusional State, Hypersensitivity, Depersonalisation, Multiple Myeloma, Pyrexia, Hepatitis, Loss of Consciousness, Hypokinesia, Spinal Compression Fracture, Skin Lesion, Inappropriate Antidiuretic Hormone Secretion, Humerus Fracture, Back Pain, Phlebitis, Pain in Extremity, Musculoskeletal Pain, Hyponatraemia, Amnesia, Epilepsy, Spondylitis, Renal Failure, Respiratory Failure, Staphylococcal Infection, Sepsis, Blood Pressure Decreased
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Depakene
Administration route: Oral
Indication: Facial Neuralgia
Start date: 2004-10-18
End date: 2004-11-01
Hydrochlorothiazide
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Start date: 1999-01-01
End date: 2004-11-01
Other drugs received by patient: Amlodipine; Irbesartan; Omeprazole; Domperidone; Nitrofurantoin; Nifedipine
Adverse event in male receiving Depakene (Valproic Acid)
Reported by a health professional (non-physician/pharmacist) from France on 2007-07-30
Patient: male
Adverse reactions / side effects: Hypersensitivity, Skin Exfoliation, Rash, Pyrexia, Erythema, Ascites, Nephritis Interstitial, Colonic Polyp, Myalgia, Renal Impairment, Arthralgia, Aspiration Bone Marrow, Lymphadenopathy Mediastinal, Pleural Effusion, Hypothyroidism, Oedema, Normochromic Normocytic Anaemia
Adverse event resulted in: hospitalization
Suspect drug(s):
Depakene (Valproic Acid)
Adverse event in 20 year old male receiving Depakene (Valproic Acid)
Reported by a consumer/non-health professional from France on 2007-05-17
Patient: 20 year old male, weighing 70.0 kg (154.0 pounds)
Adverse reactions / side effects: High Density Lipoprotein Increased, Blood Creatine Phosphokinase Increased, Lymphadenopathy, Respiratory Disorder, Corneal Neovascularisation, Skin Exfoliation, Symblepharon, Scab, Intubation, Ulcerative Keratitis, Pyrexia, Transaminases Increased, Corneal Transplant, C-Reactive Protein Increased, Dermatitis Bullous, Bone Marrow Failure, Acute Respiratory Distress Syndrome, Mucous Membrane Disorder, Thrombocytopenia, Renal Disorder, Dysphagia, Depilation, Toxic Epidermal Necrolysis, Life Support, Iris Adhesions, Blood Creatine Phosphokinase MB Increased, Prothrombin Time Ratio Decreased, Alopecia, Rash Erythematous, Asthenia, Leukopenia
Adverse event resulted in: life threatening event, hospitalization, disablity
Suspect drug(s):
Depakene
Dosage: 1.6 g daily
Indication: Partial Seizures
End date: 2004-11-22
Trileptal
Dosage: 600 mg, bid
Administration route: Oral
Indication: Partial Seizures
Start date: 2005-02-14
End date: 2005-02-21
Depakene
Dosage: 1 g daily
Administration route: Oral
Indication: Partial Seizures
Start date: 2004-11-23
End date: 2004-11-23
Depakene
Dosage: 1.5 g daily
Start date: 2004-11-24
End date: 2005-02-21
Aspegic 325
Indication: Influenza Like Illness
Start date: 2005-02-01
Other drugs received by patient: Rivotril
Adverse event in 2 year old female receiving Depakene (Valproic Acid)
Reported by a physician from United States on 2007-05-03
Patient: 2 year old female
Adverse reactions / side effects: Liver Injury, Pyrexia, Laryngeal Oedema, Cardiac Disorder, Aspiration, Hepatotoxicity, Blood Alkaline Phosphatase Increased, Pneumonia, Alanine Aminotransferase Increased, Condition Aggravated, Convulsion, Lung Disorder, Aspartate Aminotransferase Increased, Hyperammonaemia, Depressed Level of Consciousness, Increased Bronchial Secretion
Suspect drug(s):
Depakene (Valproic Acid)
Other drugs received by patient: Phenobarbital TAB; Lamictal; Topamax; Klonopin; Zantac; Pulmicort; Colace; Ceftin; Augmentin '125'; Acetaminophen; Advil; Antibiotics; Nebulizer Treatments; Steroids
Adverse event in 20 year old male receiving Depakene (Valproic Acid)
Reported by a consumer/non-health professional from France on 2007-04-27
Patient: 20 year old male, weighing 70.0 kg (154.0 pounds)
Adverse reactions / side effects: High Density Lipoprotein Increased, Blood Creatine Phosphokinase Increased, Lymphadenopathy, Corneal Neovascularisation, Skin Exfoliation, Symblepharon, Scab, Intubation, Ulcerative Keratitis, Pyrexia, Transaminases Increased, C-Reactive Protein Increased, Corneal Transplant, Dermatitis Bullous, Bone Marrow Failure, Acute Respiratory Distress Syndrome, Mucous Membrane Disorder, Thrombocytopenia, Depilation, Dysphagia, Toxic Epidermal Necrolysis, Life Support, Iris Adhesions, Blood Creatine Phosphokinase MB Increased, Prothrombin Time Ratio Decreased, Alopecia, Rash Erythematous, Asthenia, Leukopenia
Adverse event resulted in: life threatening event, hospitalization, disablity
Suspect drug(s):
Depakene
Dosage: 1.6 g daily
Indication: Partial Seizures
End date: 2004-11-22
Trileptal
Dosage: 600 mg, bid
Administration route: Oral
Indication: Partial Seizures
Start date: 2005-02-14
End date: 2005-02-21
Depakene
Dosage: 1 g daily
Administration route: Oral
Indication: Partial Seizures
Start date: 2004-11-23
End date: 2004-11-23
Depakene
Dosage: 1.5 g daily
Start date: 2004-11-24
End date: 2005-02-21
Aspegic 325
Indication: Influenza Like Illness
Start date: 2005-02-01
Other drugs received by patient: Rivotril
Adverse event in 35 year old female receiving Depakene (Valproic Acid)
Reported by a individual with unspecified qualification from France on 2007-04-11
Patient: 35 year old female, weighing 75.0 kg (165.0 pounds)
Adverse reactions / side effects: White Blood Cell Count Decreased, Agranulocytosis, Spinal Myelogram Abnormal, C-Reactive Protein Increased, Pyrexia, Neutropenia, Parotitis
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Clozapine
Dosage: 300 mg, bid
Administration route: Oral
Indication: Schizotypal Personality Disorder
Start date: 2006-03-18
End date: 2006-11-10
Depakene
Dosage: 500 mg, bid
Administration route: Oral
Start date: 2005-07-01
End date: 2006-11-10
Victan
Dosage: 1 mg, qd
Administration route: Oral
Start date: 2005-07-01
End date: 2006-11-10
Adverse event in 35 year old female receiving Depakene (Valproic Acid)
Reported by a health professional (non-physician/pharmacist) from France on 2007-04-09
Patient: 35 year old female
Adverse reactions / side effects: Agranulocytosis, Pyrexia, Parotitis, Investigation Abnormal
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Depakene
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Start date: 2005-07-01
End date: 2006-11-10
Ethyl Loflazepate
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Start date: 2005-07-01
End date: 2006-11-10
Clozapine
Administration route: Oral
Indication: Schizotypal Personality Disorder
Start date: 2006-03-18
End date: 2006-11-10
Adverse event in 52 year old male receiving Depakene (Valproic Acid)
Reported by a physician from France on 2007-04-04
Patient: 52 year old male
Adverse reactions / side effects: Drug Eruption, Pruritus, Chills, LIP Oedema, Pyrexia, Eosinophilia, Convulsion, Rash Morbilliform, Cough
Adverse event resulted in: life threatening event
Suspect drug(s):
Ciprofloxacin HCL
Administration route: Oral
Indication: Unevaluable Event
Start date: 2005-09-25
End date: 2005-09-30
Imovane
Dosage: total daily dose: 7.5 mg
Administration route: Oral
Indication: Unevaluable Event
Start date: 2005-01-01
End date: 2005-08-01
Imovane
Dosage: total daily dose: 7.5 mg
Administration route: Oral
Start date: 2005-09-22
End date: 2005-10-03
Lamictal
Administration route: Oral
Indication: Traumatic Brain Injury
Start date: 2005-09-01
End date: 2005-09-13
Lamictal
Administration route: Oral
Start date: 2005-09-07
End date: 2005-09-01
Lamictal
Administration route: Oral
Start date: 2005-09-01
End date: 2005-09-01
Lamictal
Administration route: Oral
Start date: 2005-09-13
End date: 2005-10-03
Depakene
Dosage: total daily dose: 2000 mg unit dose: 500 mg
Administration route: Oral
Indication: Traumatic Brain Injury
End date: 2005-09-11
Stablon
Administration route: Oral
Indication: Unevaluable Event
Xenetix
Indication: Prophylaxis
Start date: 2005-09-20
End date: 2005-09-20
Xenetix
Start date: 2005-10-03
End date: 2005-10-03
Other drugs received by patient: Fosamax; Orocal D3
Adverse event in 52 year old male receiving Depakene (Valproic Acid)
Reported by a consumer/non-health professional from France on 2007-04-02
Patient: 52 year old male
Adverse reactions / side effects: Hypersensitivity, LIP Disorder, Pruritus, Skin Exfoliation, Chills, Pyrexia, LIP Oedema, Cheilitis, Tongue Disorder, Oedema, Rash Morbilliform, Gastrooesophageal Reflux Disease, Oxygen Saturation Decreased, Cough, Dysphagia, Eosinophilia, Rash Maculo-Papular
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Lamictal
Administration route: Oral
Indication: Head Injury
Start date: 2005-09-07
End date: 2005-10-03
Clamoxyl
Indication: Sputum Purulent
Start date: 2005-10-12
End date: 2005-10-14
Imovane
Dosage: 7.5mg per day
Administration route: Oral
End date: 2005-10-03
Ciprofloxacin HCL
Administration route: Oral
Indication: Head Injury
Start date: 2005-09-25
End date: 2005-09-30
Depakene
Dosage: 1000mg twice per day
Administration route: Oral
Indication: Head Injury
End date: 2005-09-11
Stablon
Administration route: Oral
Iobitridol
Dosage: 120ml per day
Start date: 2005-10-03
End date: 2005-10-03
Other drugs received by patient: Fosamax; Orocal
Adverse event in 30 year old male receiving Depakene (Valproic Acid)
Reported by a health professional (non-physician/pharmacist) from France on 2007-03-08
Patient: 30 year old male
Adverse reactions / side effects: Tachycardia, Sudden Death, Neutrophilia, Pyrexia, Self Injurious Behaviour, Blood Fibrinogen Increased, Hyperhidrosis, Respiratory Tract Congestion, Cyanosis, Obstructive Airways Disorder, Blood Pressure Decreased, Wound Evisceration
Adverse event resulted in: death
Suspect drug(s):
Risperdal Consta
Indication: Schizophrenia
Tramadol HCL
Indication: Postoperative Care
Loxapac
Administration route: Oral
Indication: Schizophrenia
Clozapine Panpharma
Administration route: Oral
Indication: Schizophrenia
Depakene
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Augmentin
Indication: Drug USE FOR Unknown Indication
Other drugs received by patient: Parkinane LP; Scopoderm TTS; Seglor; Norset; Perfalgan
Adverse event in female receiving Depakene (Valproic Acid)
Reported by a health professional (non-physician/pharmacist) from France on 2007-03-07
Patient: female, weighing 58.0 kg (127.6 pounds)
Adverse reactions / side effects: Confusional State, Renal Tubular Disorder, Blood Creatine Phosphokinase Increased, Hypersensitivity, Lactic Acidosis, Pyrexia, Hypoxic Encephalopathy, Anaemia, Blood Lactate Dehydrogenase Increased, Pancytopenia, Rash, Respiratory Distress, Convulsion, Hypophosphataemia, Depressed Level of Consciousness, Angiopathy, Leukocytosis, Urine Electrolytes Abnormal
Adverse event resulted in: life threatening event
Suspect drug(s):
Kaletra
Administration route: Oral
Indication: HIV Infection
Start date: 2007-01-06
End date: 2007-01-25
Kaletra
Depakene
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Start date: 2007-01-24
End date: 2007-01-25
Depakene
Lamivudine + Zidovudine
Administration route: Oral
Indication: HIV Infection
Start date: 2007-01-06
End date: 2007-01-25
Suxamethonium Chloride
Indication: Anaesthesia
Start date: 2007-01-29
Other drugs received by patient possibly interacting with the suspect drug:
Thiopental Sodium
Indication: Anaesthesia
Start date: 2007-01-29
Other drugs received by patient: Acyclovir; Bactrim; Methadone HCL; Cefotaxime Sodium
Adverse event in 30 year old male receiving Depakene (Valproic Acid)
Reported by a health professional (non-physician/pharmacist) from France on 2007-03-01
Patient: 30 year old male
Adverse reactions / side effects: Cyanosis, Tachycardia, Sudden Death, Neutrophilia, Pyrexia
Adverse event resulted in: death
Suspect drug(s):
Risperdal Consta
Indication: Schizophrenia
Depakene
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Loxapac
Administration route: Oral
Indication: Schizophrenia
Clozapine Panpharma
Administration route: Oral
Indication: Schizophrenia
Tramadol HCL
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Augmentin '125'
Indication: Drug USE FOR Unknown Indication
Other drugs received by patient: Parkinane LP; Scopoderm TTS; Seglor; Norset; Perfalgan
Adverse event in 43 year old female receiving Depakene (Valproic Acid)
Reported by a consumer/non-health professional from France on 2007-02-16
Patient: 43 year old female, weighing 58.0 kg (127.6 pounds)
Adverse reactions / side effects: Weight Decreased, Confusional State, Hyperlactacidaemia, Blood Creatine Phosphokinase Increased, Hypersensitivity, Lactic Acidosis, Pyrexia, Blood Bicarbonate, Pneumonia Pneumococcal, Hypercapnic Encephalopathy, Mitochondrial Cytopathy, Blood Creatinine Increased, Renal Disorder, Histiocytosis Haematophagic, Hypotension, Blood Lactate Dehydrogenase Increased, Anaemia, Pancytopenia, Rash, Respiratory Distress, Convulsion, Hypophosphataemia, Depressed Level of Consciousness, Angiopathy, Leukocytosis, Urine Electrolytes Abnormal
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Combivir
Dosage: 2unit per day
Administration route: Oral
Indication: HIV Infection
End date: 2007-01-25
Clamoxyl
Dosage: 2g six times per day
Start date: 2007-01-23
End date: 2007-01-24
Claforan
Dosage: 2.5g four times per day
Start date: 2007-01-23
End date: 2007-01-24
Depakene
Administration route: Oral
Start date: 2007-01-24
End date: 2007-01-25
Kaletra
Dosage: 2unit per day
Administration route: Oral
End date: 2007-01-25
Other drugs received by patient: Zovirax; Bactrim; Methadone HCL; Urbanyl; Rivotril; Celocurin; Pentotal; Tienam; Amiklin; Gardan TAB
Adverse event in male receiving Depakene (Valproic Acid)
Reported by a health professional (non-physician/pharmacist) from France on 2007-02-10
Patient: male
Adverse reactions / side effects: Hypersensitivity, Skin Exfoliation, Rash, Pyrexia, Erythema, Ascites, Myalgia, Colonic Polyp, Nephritis Interstitial, Renal Impairment, Arthralgia, Pseudolymphoma, Pleural Effusion, Oedema, Hypothyroidism, Normochromic Normocytic Anaemia
Adverse event resulted in: hospitalization
Suspect drug(s):
Depakene (Valproic Acid)
Adverse event in 52 year old male receiving Depakene (Valproic Acid)
Reported by a health professional (non-physician/pharmacist) from France on 2007-02-09
Patient: 52 year old male
Adverse reactions / side effects: Pancreatitis Acute, Productive Cough, LIP Disorder, Lymphocyte Count Abnormal, Pruritus, Eczema, Pyrexia, Skin Test Positive, Face Oedema, Oesophagitis, Tongue Disorder, Oedema Peripheral, Oedema Mouth, Rash Morbilliform, Dysphagia, Sputum Abnormal, Blood Bicarbonate Decreased, Bronchitis Chronic, Rash Erythematous, Rhonchi, Rash Maculo-Papular, Toxic Skin Eruption, Hypersensitivity, Skin Exfoliation, Drug Ineffective, Chills, Lichenoid Keratosis, Skin Fissures, Chest X-RAY Abnormal, Skin Lesion, Pharyngolaryngeal Pain, Gastrooesophageal Reflux Disease, Prurigo, Oxygen Saturation Decreased, Computerised Tomogram Abnormal, Eosinophilia, Mucosal Erosion, Lung Disorder, Acquired Diaphragmatic Eventration, Obstructive Airways Disorder
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Depakene
Administration route: Oral
Indication: Traumatic Brain Injury
Start date: 2001-01-01
End date: 2005-09-11
Zopiclone
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
End date: 2005-08-01
Zopiclone
Administration route: Oral
Start date: 2005-09-22
End date: 2005-10-03
Ciprofloxacin
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Start date: 2005-09-25
End date: 2005-09-30
Lamotrigine
Administration route: Oral
Indication: Traumatic Brain Injury
Start date: 2005-09-07
End date: 2005-09-12
Lamotrigine
Administration route: Oral
Start date: 2005-09-13
End date: 2005-10-03
Tianeptine
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Start date: 2004-01-01
Tianeptine
Iobitridol
Indication: Abdomen Scan
Start date: 2005-09-20
End date: 2005-09-20
Iobitridol
Start date: 2005-10-03
End date: 2005-10-03
Other drugs received by patient: Alendronate Sodium; Orocal D3
Adverse event in 52 year old male receiving Depakene (Valproic Acid)
Reported by a physician from France on 2007-01-30
Patient: 52 year old male
Adverse reactions / side effects: Drug Eruption, Pruritus, Chills, LIP Oedema, Pyrexia, Eosinophilia, Convulsion, Rash Morbilliform, Cough
Adverse event resulted in: life threatening event
Suspect drug(s):
Ciprofloxacin
Administration route: Oral
Indication: Unevaluable Event
Start date: 2005-09-25
End date: 2005-09-30
Imovane
Dosage: total daily dose: 7.5 mg
Administration route: Oral
Indication: Unevaluable Event
Start date: 2005-01-01
End date: 2005-08-01
Imovane
Dosage: total daily dose: 7.5 mg
Administration route: Oral
Start date: 2005-09-22
End date: 2005-10-03
Lamictal
Administration route: Oral
Indication: Traumatic Brain Injury
Start date: 2005-09-01
End date: 2005-09-13
Lamictal
Administration route: Oral
Start date: 2005-09-07
End date: 2005-09-01
Lamictal
Administration route: Oral
Start date: 2005-09-01
End date: 2005-09-01
Lamictal
Administration route: Oral
Start date: 2005-09-13
End date: 2005-10-03
Depakene
Dosage: total daily dose: 2000 mg unit dose: 500 mg
Administration route: Oral
Indication: Traumatic Brain Injury
End date: 2005-09-11
Stablon
Administration route: Oral
Indication: Unevaluable Event
Xenetix
Indication: Prophylaxis
Start date: 2005-09-20
End date: 2005-09-20
Xenetix
Start date: 2005-10-03
End date: 2005-10-03
Other drugs received by patient: Fosamax; Orocal D3
Adverse event in 52 year old male receiving Depakene (Valproic Acid)
Reported by a consumer/non-health professional from France on 2007-01-29
Patient: 52 year old male
Adverse reactions / side effects: Hypersensitivity, LIP Disorder, Pruritus, Skin Exfoliation, Chills, Pyrexia, LIP Oedema, Cheilitis, Tongue Disorder, Oedema, Rash Morbilliform, Gastrooesophageal Reflux Disease, Oxygen Saturation Decreased, Cough, Dysphagia, Eosinophilia, Rash Maculo-Papular
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Lamictal
Administration route: Oral
Indication: Head Injury
Start date: 2005-09-07
End date: 2005-10-03
Clamoxyl
Indication: Sputum Purulent
Start date: 2005-10-12
End date: 2005-10-14
Imovane
Dosage: 7.5mg per day
Administration route: Oral
End date: 2005-10-03
Ciprofloxacin
Administration route: Oral
Indication: Head Injury
Start date: 2005-09-25
End date: 2005-09-30
Depakene
Dosage: 1000mg twice per day
Administration route: Oral
Indication: Head Injury
End date: 2005-09-11
Stablon
Administration route: Oral
Iobitridol
Dosage: 120ml per day
Start date: 2005-10-03
End date: 2005-10-03
Other drugs received by patient: Fosamax; Orocal
Adverse event in male receiving Depakene (Valproic Acid)
Reported by a health professional (non-physician/pharmacist) from France on 2007-01-27
Patient: male
Adverse reactions / side effects: Diabetes Mellitus, Skin Exfoliation, Blood Lactate Dehydrogenase Increased, Lymphopenia, Serum Ferritin Abnormal, Pyrexia, Hepatic Steatosis, Eosinophilia, Acute Generalised Exanthematous Pustulosis, Face Oedema, Oedema Peripheral, Toxic Skin Eruption
Adverse event resulted in: hospitalization
Suspect drug(s):
Depakene (Valproic Acid)
Other drugs received by patient: Silymarin; Temozolomide; Temozolomide; Prednisolone Sodium Sulfobenzoate; Prednisolone Sodium Sulfobenzoate; Glucophage; Reishi; Optiselene; Optiselene; Curcuma; Ondansetron; Gabapentin
|
